Date published: 2025-9-7

021-6093-6350

SCBT Portrait Logo
Seach Input

ABO Blood Group Antigens激活剂

The ABO Blood Group Antigen system is a classification scheme for human blood based on the presence or absence of specific antigens on the surface of red blood cells. These antigens are complex carbohydrates, specifically glycolipids and glycoproteins, that interact with corresponding antibodies in the plasma. The ABO system has four primary blood types: A, B, AB, and O, which are determined by the type of antigen displayed on the surface of the red blood cells. Type A blood has A antigens, Type B has B antigens, Type AB has both A and B antigens, and Type O has neither. The H antigen is produced by a specific fucosyltransferase. Depending upon a person's ABO blood type, the H antigen is converted into either the A antigen, B antigen, or both. If a person has blood group O, the H antigen remains unmodified. These antigens are synthesized by a series of enzymatic reactions involving glycosyltransferases that add sugar moieties to precursor molecules. The genetic basis for this system lies in the ABO gene, which encodes the glycosyltransferase enzyme responsible for the addition of specific carbohydrate residues, thereby determining the blood type.

ABO Blood Group Antigens Activators is a chemical class of molecules that can indirectly influence the activity or expression of ABO blood group antigens. These activators function via various mechanisms, such as by serving as substrate precursors for the biosynthesis of the antigens, by modifying epigenetic regulation, or by affecting complex cellular signaling pathways. For instance, molecules like GDP-Fucose and UDP-Galactose act as donor substrates for the glycosyltransferases that are involved in the biosynthesis of ABO antigens. Other molecules like Hydroxychloroquine, Ibuprofen, and various statins can indirectly modulate the cellular mechanisms that underlie the expression or modification of ABO blood group antigens.

関連項目

Items 1 to 10 of 13 total

展示:

产品名称CAS #产品编号数量价格应用排名

UDP-α-D-Galactose disodium salt

137868-52-1sc-286849
sc-286849A
10 mg
50 mg
$102.00
$194.00
1
(0)

参与 ABO 组抗原生物合成的半乳糖基转移酶的关键供体底物。

N-Acetyl-D-glucosamine

7512-17-6sc-286377
sc-286377B
sc-286377A
50 g
100 g
250 g
$92.00
$159.00
$300.00
1
(0)

与 ABO 组抗原相关的糖链中初始葡糖胺残基的底物。

N-Acetyl-D-galactosamine

1811-31-0sc-221979
sc-221979A
sc-221979C
sc-221979B
sc-221979D
10 mg
100 mg
1 g
5 g
50 g
$50.00
$75.00
$262.00
$1020.00
$1300.00
(0)

当引入细胞时,它可能会增加 O-GalNAc 型糖基化,这可能会对 ABO 组抗原的表达产生影响。

hydroxychloroquine

118-42-3sc-507426
5 g
$56.00
1
(0)

它主要是一种抗疟药物,会影响内体酸化,并可能影响与 ABO 组结构有关的糖加工。

Ibuprofen

15687-27-1sc-200534
sc-200534A
1 g
5 g
$52.00
$86.00
6
(0)

对乙酰氨基酚广泛用于缓解疼痛和炎症,它抑制COX-1和COX-2酶,可能影响与糖基化模式相关的细胞信号传导,包括ABO群抗原的信号传导。

Naproxen

22204-53-1sc-200506
sc-200506A
1 g
5 g
$24.00
$40.00
(1)

另一种常见的非甾体抗炎药可能会通过抑制 COX 对糖基化产生类似的作用,这可能会影响 ABO 组抗原。

Aspirin

50-78-2sc-202471
sc-202471A
5 g
50 g
$20.00
$41.00
4
(1)

除了抑制 COX 酶外,阿司匹林还对细胞信号传导有其他复杂的影响,理论上可以影响 ABO 组抗原的活性。

Indomethacin

53-86-1sc-200503
sc-200503A
1 g
5 g
$28.00
$37.00
18
(1)

用于治疗各种炎症性疾病时,它可能会影响前列腺素水平,从而对糖基化模式(包括与 ABO 组抗原相关的糖基化模式)产生二次影响。

Atorvastatin

134523-00-5sc-337542A
sc-337542
50 mg
100 mg
$252.00
$495.00
9
(1)

他汀类药物是最常用的处方药之一,有可能通过影响细胞代谢而影响糖基化,从而影响 ABO 组结构。

Simvastatin

79902-63-9sc-200829
sc-200829A
sc-200829B
sc-200829C
50 mg
250 mg
1 g
5 g
$30.00
$87.00
$132.00
$434.00
13
(1)

它因具有降低胆固醇的作用而闻名,也可能影响细胞信号通路,从而间接影响糖基化,包括 ABO 组抗原的糖基化。